A Dilemma for Blastocystis: Asymptomatic or Symptomatic Infection in Humans

Deepankar Srigyan1, Mandakini Gupta2 and Himansu Sekhar Behera3*

1Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India
2Centralised Accident and Trauma centre, Laxmi Nagar, New Delhi, India
3Ocular Microbiology, Dr. R.P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India

*Corresponding Author: Himansu Sekhar Behera, Ocular Microbiology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

Received: June 06, 2017; Published: June 22, 2017

Abstract

Blastocystis presents a great challenge to parasitologists and clinicians to determine whether it is truly an enteropathogen or not and treatment is required if it is observed in symptomatic patients, because even without any treatment patient recovery and improvement has been noted. Blastocystis hominis is the most common protozoan parasite found in patients with gastrointestinal symptoms and also in healthy individuals. Communities with poor hygiene, lack of safe water supply and proper sewage system show a higher prevalence. Although its distribution was almost equal in a study; 53.6% asymptomatic and 46.4% symptomatic, but in a different study from Turkey, 70.2% of patients were found symptomatic. According to some reports, in children Blastocystis infection should be considered as a prominent causative agent of gastrointestinal disturbances. B. hominis has been established as a probable causal agent in patients of Irritable Bowel syndrome. Several issues about this parasite such as the clinical relevance, pathogenicity and the need for treatment are much debated and still unresolved. Metronidazole appears to be the most effective drug for treatment of Blastocystis infections despite some evidence for treatment failure. In such circumstances, nitazoxanide and TMP-SMX may be considered as second choice of drugs.

Keywords: Blastocystis; B. hominis; Blastocystis hominis; Irritable Bowel syndrome; Metronidazole; Nitazoxanide

Abbreviations

IBS: Irritable Bowel syndrome; TMP-SMX: Trimethoprim-Sulfamethoxazole

Introduction

Blastocystis spp. are considered as a highly controversial parasite because it has been variably remarked as a commensal and pathogen in humans. Clinicians and parasitologists have for decades wondered whether to consider it as a truly enteropathogen or not and whether treatment is required if it is observed in symptomatic patients, because even without any treatment patient recovery and improvement has been noted. Treatment is needed in most of patients due to persistence of symptoms, though it is associated with self-limiting condition [1,2].

Blastocystis spp. are worldwide distributed, especially in tropical and subtropical regions. As compared with developed countries, developing countries have a higher prevalence and also it widely varies in different regions of the same country. Communities with poor hygiene, lack of safe water supply and proper sewage system show a higher prevalence. However, infection is reported in all communities and different socioeconomic groups [3-6]. Despite of being one of the most common human intestinal parasites in the developing countries, current knowledge about this protozoan is incomplete and contradictory. Several issues about this parasite such as the clinical relevance, pathogenicity and the need for treatment are much debated and still unresolved [7].

Citation: Himansu Sekhar Behera., et al. "A Dilemma for Blastocystis: Asymptomatic or Symptomatic Infection in Humans". EC Microbiology 8.5 (2017): 246-251.
This review discusses issues of *Blastocystis* in gastrointestinal disorders, its clinical relevance and diagnosis, and also provides a brief overview of antimicrobials used to target this organism.

**Clinical Significance**

*Blastocystis* is worldwide distributed and often reported as the most common intestinal protozoan. *B. hominis* is the most common in humans, has a higher prevalence (30 - 50%) in developing countries as compared to developed countries (1.5 - 10%) [3,4]. This high prevalence is related to poor hygiene, and consumption of contaminated food or water in developing countries [8].

Although *Blastocystis* was first described approximately 100 years ago, its pathogenicity and clinical relevance remains controversial. Several researchers considered it as a commensal organism, others think it is pathogenic [4,5,9]. There is lack of certain opinion to whether patients have *Blastocystis* infection are symptomatic or not. The distribution was almost equal in a study; 53.6% asymptomatic and 46.4% symptomatic [10]. But not like most research, in a study from Turkey, 70.2% of patients were found symptomatic [8]. According to some reports, in children *Blastocystis* infection should be considered as a prominent causative agent of gastrointestinal disturbances. In some studies, from different countries of world, the prevalence rates of *Blastocystis* infection among pre-school children were reported as 25% in Jordan and 18.9% in Venezuela; among the primary school children, they were 6.7% in Libya, 13.5% in Thailand, 16% in Venezuela and 22.4% in Colombia [11].

*B. hominis* as a causative agent of intestinal diseases has not yet been conclusively shown, but it has been associated with gastrointestinal disturbances such as nausea, vomiting, flatulence, discomfort, cramps, diarrhoea, abdominal pain, and is also linked to irritable bowel syndrome (IBS). Fever, urticaria and anorexia has also been reported in some cases [4,5,9]. It may cause acute, or chronic illness with symptoms persisting for several years. Travelers, immigrants, those living with poor sanitation, and people in close contact with animals are susceptible to *Blastocystis*- associated disorders. In immuno competent as well as in immunocompromised patients, a significant correlation between *Blastocystis* and gastrointestinal symptoms was detected [4,9,12].

Pathogenicity of *Blastocystis* which is a debatable topic has stimulated interest among researchers to study the epidemiological and molecular aspects of this parasite. In various studies, it has been shown that there is association between its pathogenicity, with genotypic characteristics and serious illnesses like Irritable Bowel Syndrome as well as colorectal cancer [13]. Role of *B. hominis* as an etiological agent of gastrointestinal disorder has been linked to symptoms such as chronic diarrhea and functional gastrointestinal disorder i.e. Irritable Bowel syndrome (IBS) which manifests with recurrent abdominal pain associated with changes in bowel habit [14,15].

*B. hominis* has been established as a probable causal agent in patients of Irritable Bowel syndrome [16]. Prevalence of *B. hominis* as a causal agent of IBS varies with geographical region ranging from 2.6% to 100% [16-18]. In Indian subcontinent, clinical studies on IBS so far have been reported in few studies with a prevalence of 4% to 4.2% [19,20].

**Morphology**

*Blastocystis* is highly refractile appearing like fat granules and often not identified since it is not looked for. The sizes are variable since it has different morphological forms [7]. Four different morphological forms have been described i.e. vacuolar, granular, cystic and amoeboid [4]. The vacuolar and amoeboid forms are most commonly observed in fecal specimens [21]. The amoeboid form would resemble a leukocyte. The organism is anaerobic, so it easily dies on a slide [7]. In fecal specimens, *B. hominis* is brightly refractile and of widely variable in diameter (4 - 15μ) and contains visible mitochondria and sometimes a vacuole [22].

**Diagnosis**

Diagnosis is routinely made by detecting characteristic forms of the protozoan in fecal specimens. Sometimes it may be difficult to identify the parasites in wet mounts. Lugol’s iodine mount and permanent stained preparations of fecal smears with acid-fast, trichrome, Field’s and Giemsa are the most useful methods. Among these, trichrome is the most commonly used, and the most sensitive stain com-
pared with other stains [4,5]. Previous epidemiological studies suggested that Blastocystis spp. rapidly multiplies in a culture medium with serum supplementation after 24 - 48 h of cultivation [23]. It is a strict anaerobe and requires the presence of bacteria for growth. Optimal growth of this organism occurs at 37°C at neutral pH [21]. Recently, molecular diagnostic techniques have been used in the diagnosis of this parasite, and the Real-Time PCR is found to be highly sensitive and specific for Blastocystis infection [24-26].

**Treatment**

In instances where treatment is required, metronidazole is the most commonly prescribed antibiotic. It is prescribed in different dosage regimens ranging from 250 mg to 750 mg 3 times a day, to 1.5 grams per day for 10 days. It may be used alone or in combination with other drugs like paromomycin or cotrimoxazole [4,14,28]. Large scale treatment trials are lacking as a result of this uncertainty surrounding of its pathogenic role. Despite the self-limiting nature of this infection, treatment of symptomatic patients is often warranted [11,29]. Recent data suggests that Blastocystis infection causes symptoms frequently. Therefore, treatment should be limited to patients with persistent gastrointestinal symptoms subsequent to a complete work up for alternative infections [30]. In symptomatic patients, studies reporting therapeutic improvement concomitant with parasite clearance substantiates the pathogenic role of the organism and hence, treatment required [4,31,32].

TMP-SMX has also been shown to have good effects on the clinical symptoms and the cure rate in patients with Blastocystis infection. In some reports, it is considered to be better than metronidazole in the treatment without the side-effects [33]. Nitazoxanide, a 5-nitro thiazole, broad spectrum anti-parasitic drug is also found to have potent activity against Blastocystis infection [34-36]. Metronidazole treatment failures in Blastocystis infection may well respond to nitazoxanide [27,36]. Saccharomyces boulardii is a non-pathogenic yeast, has proven effective in gastrointestinal disorders with predominant inflammatory conditions, indicating its supportive role in management of symptomatic Blastocystis infection [30,37].

**Conclusions**

*Blastocystis hominis* is the most common protozoan parasite found in patients with gastrointestinal symptoms and also in healthy individuals. In several studies, it has been shown that it is a common protozoan infection with varying levels of pathogenicity. This parasite is worldwide distributed, especially in tropical and subtropical countries. Blastocystis has a wide variety of reservoirs, and these make people more vulnerable to the infection. A comprehensive parasitological examination must be carried out in all symptomatic and asymptomatic individuals to understand the real prevalence of the disease. A number of drug treatment options are available for symptomatic Blastocystis infections. Metronidazole appears to be the most effective drug for treatment of Blastocystis infections despite some evidence for treatment failure. In such circumstances, nitazoxanide and TMP-SMX may be considered as second choice of drugs. Treatment should be instituted if the diarrhoea and other gastrointestinal symptoms are persistent and no other causative pathogen is identified in fecal samples.

**Acknowledgement**

I sincerely thanks to both of my co-authors for preparation of this review article.

**Conflict of Interests**

All the authors declare that there are no conflicts of interest related to this review article.

**Informed Consent**

Consent was obtained from all individual participants included in the presentation of review article.

**Bibliography**


**Citation:** Himansu Sekhar Behera, et al. “A Dilemma for Blastocystis: Asymptomatic or Symptomatic Infection in Humans”. *EC Microbiology* 8.5 (2017): 246-251.
A Dilemma for *Blastocystis*: Asymptomatic or Symptomatic Infection in Humans


A Dilemma for *Blastocystis*: Asymptomatic or Symptomatic Infection in Humans


34. Coyle CM., *et al.* "Blastocystis: to treat or not to treat". *Clinical Infectious Diseases* 54.1 (2012): 105-110.


*Citation*: Himansu Sekhar Behera., *et al.* "A Dilemma for *Blastocystis*: Asymptomatic or Symptomatic Infection in Humans". *EC Microbiology* 8.5 (2017): 246-251.